{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:19:44Z","timestamp":1789600784388,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.vaccine.2020.06.008","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T17:26:59Z","timestamp":1592069219000},"page":"5219-5222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Adverse events following immunization with the live-attenuated recombinant Japanese encephalitis vaccine (IMOJEV\u00ae) in Taiwan, 2017\u201318"],"prefix":"10.1016","volume":"38","author":[{"given":"Hsuan-Yin","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Chih","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-Chang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Ing","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.06.008_b0005","first-page":"69","article-title":"Japanese Encephalitis Vaccines: WHO position paper - February 2015","volume":"90","author":"World Health Organization","year":"2015","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2020.06.008_b0010","doi-asserted-by":"crossref","unstructured":"Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 2011;89:766-74, 74A-74E.","DOI":"10.2471\/BLT.10.085233"},{"key":"10.1016\/j.vaccine.2020.06.008_b0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.68.4.405","article-title":"Japanese encephalitis","volume":"68","author":"Solomon","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.vaccine.2020.06.008_b0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11908-018-0635-8","article-title":"Evolving Epidemiology of Japanese Encephalitis: Implications for Vaccination","volume":"20","author":"Caldwell","year":"2018","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.vaccine.2020.06.008_b0025","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/S0264-410X(00)00111-0","article-title":"Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group","volume":"18","author":"Takahashi","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.008_b0030","unstructured":"Taiwan CDC. Immunisation coverage annual data 2018. Available at: <https:\/\/www.cdc.gov.tw\/En\/Category\/ListPage\/4TFK95zgsUb9k8XYFFj2Dw> [Access 08 OCT 2019]. 2018."},{"key":"10.1016\/j.vaccine.2020.06.008_b0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pedneo.2019.11.009","article-title":"Recommendations for the use of Japanese encephalitis vaccines","volume":"61","author":"Lee","year":"2020","journal-title":"Pediatr Neonatol"},{"key":"10.1016\/j.vaccine.2020.06.008_b0040","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/INF.0000000000000276","article-title":"Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety","volume":"33","author":"Feroldi","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.06.008_b0045","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4161\/hv.20071","article-title":"Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12\u201318 months: randomized, controlled phase 3 immunogenicity and safety trial","volume":"8","author":"Feroldi","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.06.008_b0050","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1016\/j.vaccine.2014.02.085","article-title":"Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan","volume":"32","author":"Huang","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.008_b0055","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1016\/j.vaccine.2010.09.035","article-title":"Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials","volume":"28","author":"Torresi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.008_b0060","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/INF.0b013e3181f68e9c","article-title":"Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial","volume":"29","author":"Chokephaibulkit","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.06.008_b0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.vaccine.2016.11.062","article-title":"Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand","volume":"35","author":"Chotpitayasunondh","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.008_b0070","unstructured":"Taiwan FDA. Taiwan ADR reporting system. Available at: <https:\/\/adr.fda.gov.tw\/Manager\/WebLogin.aspx> [Access 12 June 2019]."},{"issue":"44","key":"10.1016\/j.vaccine.2020.06.008_b0075","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1016\/j.vaccine.2010.08.069","article-title":"Design of a robust infrastructure to monitor the safety of the pandemic A(H1N1) 2009 vaccination program in Taiwan","volume":"28","author":"Huang","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.008_b0080","unstructured":"Taiwan FDA. Taiwan FDA. Available at: <https:\/\/www.fda.gov.tw\/ENG\/lawContent.aspx?cid=5060&id=3156> [Access 12 June 2019]."},{"key":"10.1016\/j.vaccine.2020.06.008_b0085","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.vaccine.2014.11.046","article-title":"Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009\u20132012","volume":"33","author":"Rabe","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.008_b0090","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2215\/CJN.05960616","article-title":"Focal Segmental Glomerulosclerosis","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.vaccine.2020.06.008_b0095","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nrneph.2014.216","article-title":"Causes and pathogenesis of focal segmental glomerulosclerosis","volume":"11","author":"Fogo","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.vaccine.2020.06.008_b0100","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.008_b0105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the Vaccine Adverse Event Reporting System","volume":"23","author":"Varricchio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.06.008_b0110","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.vaccine.2012.01.013","article-title":"The reporting completeness of a passive safety surveillance system for pandemic (H1N1) 2009 vaccines: a capture-recapture analysis","volume":"30","author":"Huang","year":"2012","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20307696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20307696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:47:07Z","timestamp":1759402027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20307696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":22,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0264410X20307696"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.008","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events following immunization with the live-attenuated recombinant Japanese encephalitis vaccine (IMOJEV\u00ae) in Taiwan, 2017\u201318","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}